Volume 379, Issue 9812, Pages 229-235 (January 2012) Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial Prof Fang Gao Smith, MD, Prof Gavin D Perkins, MD, Simon Gates, PhD, Duncan Young, MD, Prof Daniel F McAuley, MD, William Tunnicliffe, FRCP, Zahid Khan, FRCA, Prof Sarah E Lamb, DPhil The Lancet Volume 379, Issue 9812, Pages 229-235 (January 2012) DOI: 10.1016/S0140-6736(11)61623-1 Copyright © 2012 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile The Lancet 2012 379, 229-235DOI: (10.1016/S0140-6736(11)61623-1) Copyright © 2012 Elsevier Ltd Terms and Conditions
Figure 2 Kaplan-Meier curves for duration of infusions Duration of salbutamol and placebo infusions from 28 days after randomisation. HR=hazard ratio. The Lancet 2012 379, 229-235DOI: (10.1016/S0140-6736(11)61623-1) Copyright © 2012 Elsevier Ltd Terms and Conditions
Figure 3 Kaplan-Meier curves for mortality Rate of death in the two study groups up to 28 days after randomisation. The Lancet 2012 379, 229-235DOI: (10.1016/S0140-6736(11)61623-1) Copyright © 2012 Elsevier Ltd Terms and Conditions